MSI Cancer Immunology Flashcards

1
Q
Hallmarks of cancer include:
Sustaining proliferative signalling
Evading growth suppressors
Activating invasion and metastasis
Enabling replicative \_\_\_\_\_\_\_\_\_\_
Inducing angiogenesis
Resisting cell death
A

immortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The development of _______ of self-antigens can result in shielding of tumours from the immune system

A

tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The two most important cells that illicit and anti-tumour effect are the ____ cells (which kills cancer cells by secreting perforin and granzymes?) followed by the ___ cells which multiply and signal other parts of the immune system to come to the site of disease via cytokines. This leads to cell death by recruitment of further NK cells and T cells

A

NK cells, T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The appearance of _____ Tumour infiltrating lymphocytes (TILs) in tumour, blood or lymph nodes usually suggests good prognosis in humans

A

CD8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The presence of _____ cells in tumours is a predictor of reduced survival

A

Treg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Higher incidence of cancer after immunosuppression, in immunodeficiency (AIDS) and _______

A

aging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Patients with SCID have _____ deficiency, which subsequently lead to tumour development (in mouse studies)

A

Rag

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

** Introduction of ___ (which is very immunogenic) into the bladder activates the immune system and results in targeting and killing of the cancer cells, with little effect on healthy cells

A

BCG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

2 types of tumour antigens have been identified on tumour cells:

A

Tumour-associated antigens (TAAs)

Tumour-specific antigens (TSAs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

NOT unique to tumour cells and may be proteins that are expressed during foetal development

antigens normally expressed only at certain stages of differentiation

may also be proteins that are expressed only at very low levels on normal cells, but overexpressed in particular tumours

describes which type of tumor antigen?

A

Tumour-associated transplantation antigens (TATAs)

OR Tumour-associated antigens (TAAs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Unique to tumour cells and are not present on normal body cells

antigens encoded by genes specifically expressed by tumours (example is a p53 mutation)

antigens encoded by variant forms of mutated genes

describes which type of tumor antigen?

A

Tumour-specific transplantation antigens (TSTAs)

OR Tumour-specific antigens (TSAs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tumour-associated transplantation Ag- mutation generates new peptide in class I MHC molecule. Also known as

A

neoantigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Overexpression of a normal protein represents which time of tumor antigen?

A

Tumour-associated transplantation antigens (TATAs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Inappropriate expression of embryonic gene represents what type of tumour antigen?

A

Tumour-associated transplantation antigens (TATAs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

If a mutation generates a new peptide in class I MHC molecule, this represents what type of tumour antigen?

A

Tumour-specific transplantation antigens (TSTAs) (also known as neoantigens)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Know that there are different types of tumour antigens that have potential consequences for cancer therapies:

A

Tissue differentiation Ags (TAA),
tumour germline “tumour-testis” Ags (TAA),
normal proteins overexpressed by cancer cells (TAA), Viral proteins (TSA),
or tumour-mutated Ags (TSA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Note that tumour germline antigens are not recognized in the ________, as those cells do not express Class I MHC.

A

testis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Examples of tumour-specific mutated antigens (only expressed in tumour cells as a result of mutation):

A

Ras, p53

19
Q

Innate responses to tumours(not MHC restricted):
_________ cells
Can kill directly tumour cells, helped by interferon-alpha and -beta and IL-2
Macrophages
Can infiltrate tumour masses; known as tumour-associated macrophages (TAMs). Can be pro-
tumourigenic or anti-tumourigenic.

A

Natural killer (NK)

20
Q

Adaptive responses to tumours (T cell responses are MHC restricted)
________ T-cells
Can directly kill tumour cells via tumour antigen recognition
T helper cells
Produce a variety of cytokines that activate other types of immune cell
e.g. Interferon-gamma & TNF (macrophages); IL-2 (CD8+ T cells and NK cells)
B cells
Production of tumour-specific antibodies (may be functional or not)

A

Cytotoxic

21
Q

CD8 T cell activated by specific antigen presented by APC plus co-stimulation via ______/CD86 molecules

Activation results in production of IL-2 which drives proliferation

A

CD80

22
Q

In-built mechanisms of control of T cell responses:
Inhibitory receptors expressed by T cells – these interfere with co-stimulatory signalling

Examples are:
CTLA-4 (during activation): ligand is ___ molecules
PD-1 (during effector function): ligand is PD-L1
FAS: ligand is FASL

A

B7

23
Q

CTLA-4 binds B7 more avidly than does CD28 and delivers __________ signals to activated T cells

A

inhibitory

24
Q

A tumour mass consists of:
a heterogeneous population of cancer cells with varying degrees of mutation
a variety of resident and infiltrating host cells
secreted factors and extracellular matrix proteins
This is collectively known as the

A

tumour microenvironment.

25
Q

The tumour micro-environment refers to the normal cells, molecules, and ___________that surround and feed tumour cells.

A

blood vessels

26
Q

Factors such as TGF-beta, PD-L1 secreted by tumour cells can _____ T cells directly

A

inhibit

27
Q

Cytotoxic T cells refer to CD8+ T cells that have been activated via recognition of specific antigen presented on MHC ________ – also known as CTLs.

A

Class I

28
Q

The immune system can recognize cancer cells

Most relevant immune responses mediated by NK cells and ______ T cells

Recognition by immune cells can occur via altered cell surface molecules or via tumour antigens

A

cytotoxic

29
Q

the immune system’s ability to recognize and destroy emerging cancer cells

A

Cancer immunosurveillance

30
Q

Theory that describes how the immune system can kill cancer cells; but can also induce changes in the tumour resulting in tumour cell escape and further growth of tumour mass (by epigenetic changes or Darwinian selection)

A

Cancer immunoediting theory

31
Q

What are the “3 E’s” of cancer immunoediting?

A

Elimination, equilibrium, escape

32
Q

One way that tumour cells “escape” from T cell recognition is via loss of _______

A

MHC I

33
Q

Some tumour cells develop into cells that express very low (or none) levels of MHC Class I and these cells are not recognized by cytotoxic T cells so can survive and proliferate = _______ phase

A

Escape

34
Q

Some tumour cells develop into cells that express only moderate levels of MHC Class I and so survive for longer than those expressing higher levels, but are eventually killed by cytotoxic T cells (4). As these moderately MHC expressing cells survive longer before being killed, they have longer to proliferate and so generate new cancer cells before eventually being killed = ___________ phase of the 3Es model where the tumour mass is in dynamic equilibrium with the immune system.

A

Equilibrium

35
Q

The tumour cells express MHC Class I on their surface at normal levels and present tumour antigens via these MHC molecules which are recognised by cytotoxic T cells.
Some of the tumour cells develop into cells expressing higher levels of MCH Class I molecules and so are recognised and killed by cytotoxic T cells faster than other cells in the tumour. This killing of these tumour cells may reduce the size of the tumour mass = ____________ phase of the 3Es model.

A

Elimination

36
Q

** Mechanisms of tumour escape:
Reduced levels or absence of MHC I molecules on tumour so that they can not be recognized by cytotoxic T cells

Some tumours stop expressing the antigens recognized by immune system
These tumours are called “_____ ______ ______”

Production of immunosuppressive factors by tumor e.g. transforming growth factor (TGF-β), PD-1 ligand (PD-L1)

A

antigen loss variants

37
Q

Tumour evasion mechanisms of the immune system:

Low immunogenicity (Low/absent MHC 1): No peptide: MHC ligand, no adhesion molecules, no co-stimulatory molecules

Antigenic __________ (Ag-loss variants)- Ab against tumour cell-surface Ags can induce endocytosis and degradation of the Ag. Immune selection of Ag-loss variants.

Tumour-induced immune suppression (direct suppression of CTLs)- Factors such as TGF-beta and PD-L1 secreted by tumour cells inhibit cells directly

A

modulation

38
Q

Homeostatic mechanisms aimed at preventing excessive inflammation and tissue damage

A

Immunological checkpoints.

Immune checkpoints prevent the immune response from completely eliminating the pathogen or destroying the tumour.

39
Q

What is a CAR-T cell?

A

Chimeric antigen receptors which have been engineered to graft an arbitary specificity to an effector cell (T cell)
CARs include three parts: an extracellular antigen recognition domain of the single-chain Fragment variant (scFv) derived from an antibody), a transmembrane domain and an intracellular T cell activation domain of CD3ζ

40
Q

How are the CAR-Ts introduced?’

Two ways to accomplish gene incorporation with vectors:

A

Viral and Non-viral

41
Q

How do CAR-T’s work?’

A

works by triggering the immune system to recognize tumours and thus activates cancer cell lysis

42
Q

Structure of a CAR-T

ScFv -an antibody fragment replacing the TCR which will recognize the tumor associate antigen (TAA)

___ is the signaling domain that will activate the immune response once the antigen bind to the scFv

A

CD3

43
Q

Side effects of immunotherapies

A

Complicated by severe immunosuppression/ cytokine release syndromes

44
Q

Immune evasion mechanisms by tumours include reduced tumour antigen presentation and local immunoregulatory factors: inhibitory ________ and cells

A

cytokines